Caisse de depot et placement du Quebec Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Caisse de dépôt et placement du Québec initiated a position in Edwards Lifesciences, buying 967,537 shares valued at approximately $87.5 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds, producing a “Moderate Buy” consensus and an average price target of $100.27.
• Edwards exceeded quarterly expectations, reporting $0.78 in earnings per share versus the $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. Shares opened at $90.93, while insiders sold a combined 2,425 shares over the past three months.

Caisse de depot et placement du Quebec bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 967,537 shares of the medical research company's stock, valued at approximately $87,523,000. Caisse de depot et placement du Quebec owned approximately 0.17% of Edwards Lifesciences as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $11,168,000. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $803,686,000. Conway Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $954,000. Finally, TD Asset Management Inc grew its position in Edwards Lifesciences by 6.4% in the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company's stock worth $66,335,000 after acquiring an additional 47,051 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Mizuho lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Evercore reaffirmed an "outperform" rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $100.27.

Insiders Place Their Bets

In related news, SVP Andrew M. Dahl sold 568 shares of the firm's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company's stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,425 shares of company stock valued at $219,199 over the last three months. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Trading Up 0.1%

Shares of NYSE EW opened at $90.93 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market cap of $52.36 billion, a price-to-earnings ratio of 52.26, a PEG ratio of 2.38 and a beta of 0.85. The business's 50 day moving average price is $89.43 and its 200-day moving average price is $84.91.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences's revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source